Results 71 to 80 of about 183,958 (171)

Pembrolizumab-induced asthma exacerbation with hypereosinophilia and elevated interleukin-5 in endometrial cancer: A case report

Respiratory Medicine Case Reports
Pembrolizumab is an anti-programmed cell death-1 (PD-1) antibody used to treat various cancer types. Treatments with such immune checkpoint inhibitors cause immune-related adverse events.
Tomoya Harada, Naoki Uetani, Genki Inui, Hiroki Ishikawa, Yoshihiro Funaki, Miki Takata, Ryota Okazaki, Kosuke Yamaguchi, Masato Morita, Shin Kitatani, Akira Yamasaki   +10 more
doaj   +1 more source

Vitiligo-like lesions located over In-transit metastases of malignant melanoma as a clinical marker of complete response to pembrolizumab. [PDF]

, 2019
Anti-programmed cell death (PD)-1 therapies in metastatic tumors have a high incidence of immune adverse events, including cutaneous manifestations such as vitiligo-like lesions. This side effect is associated with increased survival and it is a clinical
Gracia-Cazaña, Tamara, Hernández-García, Alba, Padgett, Esteban, Sánchez-Salas, María Pilar   +3 more
core  

Pembrolizumab Versus High-Dose Interferon-α2b as Adjuvant Therapy for Pediatric Melanoma: A Retrospective Study

Dermatology Practical & Conceptual
Introduction: Pembrolizumab is well-tolerated in pediatric patients with advanced tumors, consistent with results in adults. However, information on the safety and efficacy of adjuvant pembrolizumab in children and adolescents with melanoma is lacking.
Yu Du, Zhonghui Qi, Xianbin Liang , Jie Dai, Xiaoting Wei , Xue Bai , Lili Mao, Zhihong Chi , Chuanliang Cui, Bin Lian, Bixia Tang , Xuan Wang , Yu Chen , Jun Guo , Lu Si   +14 more
doaj   +1 more source

Baseline T cell dysfunction by single cell network profiling in metastatic breast cancer patients. [PDF]

, 2019
BackgroundWe previously reported the results of a multicentric prospective randomized trial of chemo-refractory metastatic breast cancer patients testing the efficacy of two doses of TGFβ blockade during radiotherapy.
Demaria, Sandra, Dixit, Neha, Evensen, Erik, Formenti, Silvia C, Goldberg, Judith D, Hawtin, Rachael E, Lee, Percy, Li, Xiaochun, McBride, William H, Schaue, Dörthe, Vanpouille-Box, Claire   +10 more
core   +1 more source

Estimating efficacy of favezelimab plus pembrolizumab relative to pembrolizumab in anti–PD-1–refractory Hodgkin lymphoma

Blood Advances
: Favezelimab plus pembrolizumab had promising efficacy in anti–programmed cell death protein 1 (PD-1)–refractory classical Hodgkin lymphoma in MK-4280-003; however, the contribution of favezelimab was unclear. Here, we assessed the relative contribution
Philippe Armand, Pier Luigi Zinzani, John Timmerman, Nathalie A. Johnson, David Lavie, Kannan Thiagarajan, Brian G. Topp, Pallavi Pillai, Alex F. Herrera   +8 more
doaj   +1 more source

Acute Tubulointerstitial Nephritis: A Case Report on Rare Adverse Effect of Pembrolizumab

Medicina, 2019
Pembrolizumab is a novel immune checkpoint inhibitor approved for use in non-small cell lung carcinoma. There have been a few cases that have associated adverse renal outcomes with pembrolizumab.
Sijan Basnet, Rashmi Dhital, Biswaraj Tharu   +2 more
doaj   +1 more source

Long-Term Efficacy of Pembrolizumab and the Clinical Utility of ctDNA in Locally Advanced dMMR/MSI-H Solid Tumors

Nature Communications
Neoadjuvant immunotherapy can induce pathologic complete response (pCR) in patients with localized deficient mismatch repair (dMMR)/microsatellite instability-high (MSI-H) tumors.
Michael LaPelusa, Wei Qiao, Bryan Iorgulescu, Francis San Lucas, Keyur Patel, Deepak Bhamidipati, Jane Varkey Thomas, Nancy You, Wai Chin Foo, Dipen Maru, Selvi Thirumurthi, Van Morris, Scott Kopetz, Michael Overman, Kaysia Ludford   +14 more
doaj   +1 more source

Effectiveness and safety of pembrolizumab, nivolumab, and atezolizumab as adjuvant therapy for high-risk muscle-invasive urothelial carcinoma: an indirect comparison

Frontiers in Oncology
BackgroundThe effectiveness of immune checkpoint inhibitors (ICIs) as adjuvant therapy for muscle-invasive urothelial carcinoma (MIUC) with high recurrence risk has been demonstrated.
Wei Chen, Wei Chen, Soichiro Yoshida, Noriyoshi Miura, Shohei Fukuda, Hiroshi Fukushima, Yuma Waseda, Hajime Tanaka, Yasuhisa Fujii   +8 more
doaj   +1 more source

Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma. [PDF]

, 2019
The clinical deployment of immune checkpoint inhibitors (ICIs) has created a tandem drive for the identification of biomarkers linked to benefit. Comprehensive genomic profiling was performed to evaluate the frequency of genomic biomarkers of ICI ...
Ali, Siraj M, Ang, Celina, Fabrizio, David, Goodman, Aaron, Klempner, Samuel J, Kurzrock, Razelle, Madison, Russell, Millis, Sherri Z, Ross, Jeffrey S, Severson, Eric A, Suh, James   +10 more
core   +1 more source

Revisiting Epidermal Growth Factor Receptor (EGFR) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies. [PDF]

, 2019
PurposeTo date, evidence for tissue epidermal growth factor receptor (EGFR) overexpression as a biomarker for anti-EGFR therapies has been weak. We investigated the genomic landscape of EGFR amplification in blood-derived cell-free tumor DNA (cfDNA ...
Fanta, Paul T, Goodman, Aaron, Kato, Shumei, Kurzrock, Razelle, Lanman, Richard B, Lee, Suzanna, Lippman, Scott M, Mareboina, Manvita, Okamura, Ryosuke, Patel, Sandip P, Raymond, Victoria M, Schwab, Richard B, Sicklick, Jason K, Vu, Peter   +13 more
core   +1 more source